ADC Therapeutics SA

General Information


We are a late clinical-stage oncology-focused biotechnology company evolving into a commercial-stage company as we prepare for the launch of our lead product candidate, if approved. We are a pioneer in the development of highly potent and targeted ADCs for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation PBD technology to which we have proprietary rights for our targets.

Employees: 138
Founded: 2011
Contact Information
Address Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland
Phone Number +41 21 653 02 00
Web Address
View Prospectus: ADC Therapeutics SA
Financial Information
Market Cap $1136.8mil
Revenues $2.34 mil (last 12 months)
Net Income $-116.5 mil (last 12 months)
IPO Profile
Symbol ADCT
Exchange NYSE
Shares (millions): 12.3
Price range $19.00 - $19.00
Est. $ Volume $232.8 mil
Manager / Joint Managers Morgan Stanley/ BofA Securities/ Cowen and Company
CO-Managers -
Expected To Trade: 5/15/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change